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Neisseria 
meningitidis 
Serogroup X 
Sequence Type 
2888, Italy 
To the Editor:  Neisseria men-
ingitidis serogroup X was ﬁ  rst  de-
scribed in the 1960s and has been 
found to be responsible of rare cases 
of invasive meningococcal diseases, 
in particular, meningitis, in North 
America, Europe, Australia, Africa, 
and the People’s Republic of China 
(1–3). This serogroup has recently 
emerged in Africa as an increasing 
cause of meningitis; unfortunately, it 
is not covered by current vaccine pro-
grams. Serogroup X outbreaks have 
been reported in Niger, Ghana, and 
Kenya (4–6). In particular, in Niger 
during January–June 2006, N. menin-
gitidis serogroup X represented 51% 
of conﬁ  rmed cases of meningitis (4).
To investigate the population 
structure of serogroup X meningo-
cocci isolated during recent decades 
in Africa, Europe, and North America, 
Gagneux et al. (1) compared the mo-
lecular characteristics among them. 
That study highlighted a low genetic 
variability between African serogroup 
X strains, which contrasts with higher 
genetic variability among isolates from 
Europe and the United States (1).
We describe a case of invasive 
meningococcal disease caused by a 
serogroup X N. meningitidis strain 
isolated in Italy. The patient was a 
55-year-old Italian woman with no 
immune deﬁ  ciency. The onset of dis-
ease started quickly with high fever 
(39°C) on June 1, 2009. No contacts 
with persons coming from abroad 
were reported. This case was diag-
nosed on the basis of clinical signs 
and symptoms and results of labo-
ratory conﬁ   rmatory tests, including 
blood culture. The patient received 
ceftriaxone (2 g/day) for 7 days with 
a favorable outcome.
The strain was susceptible to pen-
icillin G, rifampin, ciproﬂ  oxacin, and 
ceftriaxone, as determined by Etest 
method (bioMérieux, Florence, Italy). 
The breakpoints were those recom-
mended by the Clinical and Labora-
tory Standards Institute (7). Serogroup 
was determined by serum agglutina-
tion, and serotype/subtype, NT:P1.15, 
19 were determined by standard 
whole-cell ELISA with monoclonal 
antibodies (obtained from the National 
Institute for Biological Standards and 
Control, South Mimms, UK) (8).
PorA variable regions, FetA, and 
multilocus sequence typing analyses 
were performed according to stan-
dard procedures from the Neisseria 
Multi Locus Sequence Typing Web 
site (http://pubmlst.org/neisseria). The 
isolate from Italy had the pattern PorA 
VR1–19, VR2–15, and VR3–36; F5–5 
and sequence type (ST)-2888. The 
same ST was already described in 
Greece in 2002 but in a noninvasive 
strain (http://pubmlst.org/neisseria).
The pattern obtained by pulsed-
ﬁ  eld gel electrophoresis (9), using the 
rare-cutting enzyme NheI, (data not 
shown), was identical to patterns found 
among meningococci X strains isolated 
in United Kingdom and belonging to 
ST-750, clonal group X-II (1). In par-
ticular, ST-2888 resembles, except for 
gdh gene sequence, ST-2317, which 
was found among the X meningococ-
ci isolated in the United Kingdom in 
2002 with phenotype X:4:P1.7 (http://
pubmlst.org/neisseria). 
Our data document a rare case of 
invasive meningococcal meningitis in 
Italy, caused by N. meningitidis sero-
group X ST-2888. Future surveillance 
data may be able to determine epide-
miologic inﬂ  uences, likely emanating 
from nearby countries, on the spread 
of such a strain into Italy. 
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Antiphospholipid 
Syndrome and 
Acute HIV Infection
To the Editor: Patients with acute 
HIV infection frequently experience a 
syndrome characterized by fever, sore 
throat, lymphadenopathy, maculopap-
ular rash, and lymphomonocytosis, 
which mimics acute infectious mono-
nucleosis, 3–6 weeks after primary 
infection (1). Aseptic meningitis, en-
cephalitis, and peripheral neuropa-
thy are the most commonly observed 
features. In contrast, antiphospholipid 
syndrome complicated with pulmo-
nary emboli is not commonly associ-
ated with acute retroviral syndrome. 
The following case should prompt cli-
nicians to consider an expanded clini-
cal scope of initial signs and symp-
toms for acute HIV infection.
A 28-year-old homosexual man 
was admitted to a hospital in Madrid, 
Spain, on June 22, 2009, with fever, 
pharyingitis, and myalgias. General-
ized lymphadenopathy was found on 
examination. Lymphomonocytosis and 
mild elevation of serum aspartate ami-
notransferase and serum alanine amin-
otransferase levels were found. Chest 
radiographs showed no abnormalities. 
Results of a commercial ELISA for 
HIV-1 and HIV-2 were negative. Re-
sults of a p24 antigen-capture assay 
were positive, and viral load measured 
by reverse transcription–PCR (RT-
PCR, Amplicor; Roche Molecular 
Diagnostics, Pleasanton, CA, USA) 
was 2,600,000 copies RNA HIV/mL. 
CD4+ T-cell count was 297 cells/μL.
The patient was discharged with 
instructions to take acetaminophen, 
but he was readmitted 1 week later 
with recurring fever, pleuritic chest 
pain, and shortness of breath. He was 
febrile (38.5ºC), tachycardic, and 
tachypneic and had a blood pressure 
of 155/72 mm Hg and generalized 
lymphadenopathy. Blood tests showed 
a hemoglobin level of 10.6 g/dL, leu-
kocyte count of 5,160 cells/μL, and 
thrombocyte count of 293 cells/μL. 
Results of renal function tests were 
within normal limits as were serum 
aminotransferase levels. Lactate dehy-
drogenase level was 698 IU/L (refer-
ence range 211–423 IU/L) and D-di-
mer was 3,414 μg/L (reference range 
68–494 IU/L). Fibrinogen levels, pro-
thrombin time, and partial thrombo-
plastin time were normal. Chest radio-
graphs showed a small area of pleural 
effusion on the left side. A computed 
tomographic scan of the chest showed 
multiple pulmonary emboli with areas 
of parenchymal infarction.
Antibodies against phospholipids 
(PLs) and β2-glycoprotein I (β2GPI) 
measured by ELISA were detected at 
high titers: immunoglobulin (Ig) M 
anticardiolipin + 72 U MPL/mL (posi-
tive at >20 U MPL/mL), IgG anticar-
diolipin + 158 U GLP/mL (positive 
at >20 U GLP/mL), IgG anti-β2GPI + 
210 U/mL (positive at >10). Results of 
screening tests for thrombophilia and 
other autoantibodies were within nor-
mal limits.
The patient was treated with low 
molecular weight heparin, oxygen, and 
analgesics. His fever subsided, and he 
was discharged a few days later while 
continuing to receive acenocoumarol, 
an oral coumarin anticoagulant. Re-
sults of a repeated HIV ELISA were 
then positive. Western blot assay con-
ﬁ  rmed the presence of antibodies to 
p24, gp41, and gp120/160.
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